289 related articles for article (PubMed ID: 32733387)
1. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.
Zielinski G; Ozdarski M; Maksymowicz M; Szamotulska K; Witek P
Front Endocrinol (Lausanne); 2020; 11():439. PubMed ID: 32733387
[No Abstract] [Full Text] [Related]
2. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
4. Microprolactinomas in males treated by transsphenoidal surgery.
Wolfsberger S; Czech T; Vierhapper H; Benavente R; Knosp E
Acta Neurochir (Wien); 2003 Nov; 145(11):935-40; discussion 940-1. PubMed ID: 14628197
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery.
Amar AP; Couldwell WT; Chen JC; Weiss MH
J Neurosurg; 2002 Aug; 97(2):307-14. PubMed ID: 12186458
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
[TBL] [Abstract][Full Text] [Related]
7. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.
Han YL; Chen DM; Zhang C; Pan M; Yang XP; Wu YG
Medicine (Baltimore); 2018 Nov; 97(45):e13198. PubMed ID: 30407358
[TBL] [Abstract][Full Text] [Related]
9. The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus.
Abou-Al-Shaar H; Mallela AN; Patel A; Shariff RK; Shin SS; Choi PA; Faraji AH; Fazeli PK; Costacou T; Wang EW; Fernandez-Miranda JC; Snyderman CH; Gardner PA; Zenonos GA
Pituitary; 2022 Jun; 25(3):508-519. PubMed ID: 35467273
[TBL] [Abstract][Full Text] [Related]
10. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results.
Tyrrell JB; Lamborn KR; Hannegan LT; Applebury CB; Wilson CB
Neurosurgery; 1999 Feb; 44(2):254-61; discussion 261-3. PubMed ID: 9932878
[TBL] [Abstract][Full Text] [Related]
11. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
12. Transsphenoidal microsurgical results of female patients with prolactinomas.
Ikeda H; Watanabe K; Tominaga T; Yoshimoto T
Clin Neurol Neurosurg; 2013 Sep; 115(9):1621-5. PubMed ID: 23498159
[TBL] [Abstract][Full Text] [Related]
13. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
15. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases.
Qu X; Wang M; Wang G; Han T; Mou C; Han L; Jiang M; Qu Y; Zhang M; Pang Q; Xu G
Eur J Endocrinol; 2011 Apr; 164(4):499-504. PubMed ID: 21252173
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
[TBL] [Abstract][Full Text] [Related]
17. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of curative effect of surgical therapy for male prolactinoma].
Chen MT; Song YJ; Lian W; Xing B; Yao Y; Feng M; Wang RZ
Zhonghua Yi Xue Za Zhi; 2016 May; 96(19):1477-80. PubMed ID: 27266490
[TBL] [Abstract][Full Text] [Related]
19. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
Park JY; Choi W; Hong AR; Yoon JH; Kim HK; Jang WY; Jung S; Kang HC
Pituitary; 2021 Dec; 24(6):955-963. PubMed ID: 34189717
[TBL] [Abstract][Full Text] [Related]
20. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]